Viking Therapeutics, Inc. announced several senior level appointments designed to strengthen the company's leadership as it continues to advance its pipeline of clinical and preclinical development programs. The company has appointed Amy Broidrick as Senior Vice President of Corporate Development, Greg Zante as Vice President of Finance and Operations, and Catherine (Cass) Lee Kelleher, M.D., as Vice President of Clinical Development. Collectively, these individuals bring Viking significant industry experience in areas directly related to the company's ongoing programs in the fields of metabolic and endocrine disorders. Before joining Viking, Broidrick served as Vice President and Head of Global Marketing Excellence and Business Innovation at EMD Serono, Inc, part of Merck KGaA (Germany). Prior to her position at EMD Serono, Ms. Broidrick was Vice President and Head of Marketing and Commercialization at Arena Pharmaceuticals. She has also held roles of increasing responsibility at Merck & Co. and Pfizer (formerly GD Searle). In his new role, Zante will be responsible for forecasting, scenario analyses, financing strategies, business development support and operational activities. Prior to Viking, Mr. Zante was Chief Financial Officer at Dance Biopharm. Mr. Zante has also previously held senior positions at several biopharmaceutical companies including Sangamo BioSciences, Calyx Therapeutics and Matrix Pharmaceuticals. Kelleher expertise in the areas of metabolic disorders and gerontology aligns with Viking's clinical development programs which she will be charged with managing in her new role as Vice President of Clinical Development. Most recently, Dr. Kelleher served as Vice President of Clinical Development at Coherus BioSciences. Previously, she served as Head of Clinical for the United States at Proteus Digital Health, Inc. Prior to this she worked as a global safety officer for inflammation and oncology and also a clinical research medical director in nephrology at Amgen.